Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Anti-idiotypic
Reexamination Certificate
2006-12-12
2006-12-12
Huff, Sheela J. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Anti-idiotypic
C424S130100, C424S138100, C424S137100, C424S139100, C424S141100, C424S174100
Reexamination Certificate
active
07147850
ABSTRACT:
The invention provides therapeutic compositions comprising binding agents that specifically bind to tumor-associated MUC-1 and reduce, reverse or prevent their effects in cancer. More particularly, the invention provides therapeutic compositions that comprise a binding agent that can specifically bind to an epitope that comprises both peptide and carbohydrate on such tumor-associated MUC-1. The invention further provides methods for the use of such therapeutic compositions in the treatment of cancer.The invention also provides methods for therapeutically treating a mammal bearing a tumor comprising administering to the mammal an effective amount of a therapeutic composition consisting essentially of a binding agent that specifically binds to an epitope of tumor-associated MUC1, wherein the mammal generates an immune response that comprises an antibody that specifically binds to an epitope of tumor-associated MUC1 that is different from the epitope of tumor associated MUC1 that is specifically bound by the binding agent.
REFERENCES:
patent: 5506343 (1996-04-01), Kufe
patent: 6235280 (2001-05-01), Chatterjee et al.
patent: 6716966 (2004-04-01), Madiyalakan
patent: 98/33470 (1998-08-01), None
Herlyn et al Cancer Immunol. Immunother. (1996) 43:65-76.
Knight, BioTechnology vol. 7 No. 1, Jan. 1989 p. 36.
Price, M.R. and Tendler, S.J.B. Polymorphic epithelial mucins (PEM): molecular characteristics and association with breast cancer. Breast 2, 3-7 (1993).
Burchell, J. et al. Detection of the Tumour-Associated Antigens Recognized by the Monoclonal Antibodies HMFG-1 and 2 in Serum From Patients with Breast Cancer Int. J. Cancer 34, 763-768 (1984).
Burchell, J. et al. Active Specific Immunotherapy: PEM as a Potential Target Molecule, Cancer Surv. 18, 135-148 (1993).
Codington, J.F. and Frim, D.M. “Cell-Surface Macromolecular and Morphological Changes Related to Allotransplantability in the TA3 Tumor” in Biomembranes, L.A. Mansoe, ed. Plenum Pub. Corp., N.Y. p. 207-259 (1983).
Devine, P.L. and Mackenzie, I.F.C. Mucins: Structurue, Function, and Associations with Malignancy. BioEssays 14, 619-625 (Sep. 1993).
Gendler, S.J. et al. Cloning of partial cDNA encoding differentiation and tumor-associated mucin glycoproteins expressed by human mammary epithelium. PNAS 84, 6060-6064 (Sep. 1987).
Gendler, S.J. et al. Molecular Cloning and Expression of Human Tumor-associated Polymorphic Epithelial Mucin. J. Biol. Chem. 265, 15286-15293 (Sep. 5, 1990).
Ho, S.B. et al. Heterogeneity of Mucin Gene Expression in Normal and Neoplastic Tissues. Cancer Res. 53, 641-651 (Feb. 1, 1993).
Hull, S.R. et al. Oligosaccharide Differences in the DF3 Sialomucin Antigen from Normal Human Milk and the BT-20 Human Breast Carcinoma Cell Line. Cancer Commun. 1, 261-267 (1989).
Jentoff, N. Why are proteins O-glycosylated? TIBS 15, 291-294 (Aug. 1990).
Lightenberg, M.J.L. et al. Episialin, a Carcinoma-associated Mucin, is Generated by a Polymorphic Gene Encoding Splice Variants with Alternative Amino Termini. J. Biol. Chem. 265, 5573-5578 (Apr. 5, 1990).
Linsley, P.S. et al. Elevated Levels of a High Molecular Weight Antigen Detected by Antibody WI in Sera from Breast Cancer Patients. Cancer Res. 46, 5444-5450 (Oct. 1986).
Magnani, J.L. et al. Identification of the Gastrointestinal and Pancreatic Cancer-associated Antigen Detected by Monoclonal Antibody 19-9 in the Sera of Patients as a Mucin. Cancer Res. 43, 5489-5492 (Nov. 1983).
Metzgar, R.S. et al. Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma. PNAS 81, 5242-5246 (Aug. 1984).
Miller, S.C. et al. Ultrastructural and Histochemical Differences in Cell Surface Properties of Strain-Specific and Nonstrain-Specific TA3 Adenocarcinoma Cells J. Cell Biol. 72, 511 (1977).
Neutra, M.R. and Forstner, J.F. “Gastrointestinal Mucus: Synthesis, Secretion, and Function” in Physiology of the Gastrointestinal Tract, 2ndedition, L.R. Johnson, ed. Raven Press, N.Y. p. 975-7009 (1987).
Parry, G. et al. Determination of Apical Membrane Polarity in Mammary Epithelial Cell Cultures: The Role of Cell-Cell, Cell-Substratum, and Membrane-Cytoskeleton Interactions. Exp. Cell Res. 188, 302-311 (1990).
Pihl, E. et al. Mucinous Corectal Carcinoma: Immunopathology and Prognosis. Pathol. 12, 439-437 (1980).
Regimbald, L.H. et al. The Breast Mucin MUC1 as a Novel Adhesion Ligand for Endothelial Intercellular Adhesion Molecule 1 in Breast Cancer. Cancer Res. 56, 4244-4249 (Sep. 15, 1996).
Rittenhouse, H.G. et al. Mucin-Type Glycoproteins as Tumor Markers. Lab Med. 16, 556-560 (Sep. 1985).
Siddiqui, J. et al. Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. PNAS 85, 2320-2323 (Apr. 1988).
Wong, R.C.K. et al. Signal Transduction via Leukocyte Antigen CD43 (Sialophorin): Feedback Regulation by Protein Kinase C1. J. Immunol. 144, 1455-1460 (Feb. 15, 1990).
AltaRex Medical Corp.
Fish & Neave IP Group Ropes & Gray LLP
Huff Sheela J.
LandOfFree
Therapeutic binding agents against MUC-1 antigen and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic binding agents against MUC-1 antigen and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic binding agents against MUC-1 antigen and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3719953